What's New in SCLC? A Review

A few years ago the answer to the question in the title of this review would have been, “unfortunately not much” or even “nothing”, likely eliciting knowing nods of agreement from oncologists. For the last 3 decades, SCLC has been notorious for its lack of progress, as drug after drug, over 60 of th...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Neoplasia (New York, N.Y.) Ročník 19; číslo 10; s. 842 - 847
Hlavní autoři:	Oronsky, Bryan, Reid, Tony R., Oronsky, Arnold, Carter, Corey A.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Elsevier Inc 01.10.2017 Elsevier Limited Neoplasia Press Elsevier
Témata:	Clinical trials DNA-directed RNA polymerase Drug development Epidemiology Epidermal growth factor receptors Humans Immune checkpoint Immunotherapy Lung Neoplasms - diagnosis Lung Neoplasms - epidemiology Lung Neoplasms - etiology Lung Neoplasms - therapy Molecular Targeted Therapy Neoplasm Staging Non-small cell lung carcinoma Poly(ADP-ribose) polymerase Prevalence Prognosis Review article Reviews RNA polymerase Small cell lung carcinoma Small Cell Lung Carcinoma - diagnosis Small Cell Lung Carcinoma - epidemiology Small Cell Lung Carcinoma - etiology Small Cell Lung Carcinoma - therapy TOR protein Treatment Outcome Vascular endothelial growth factor
ISSN:	1476-5586, 1522-8002, 1476-5586, 1522-8002
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	A few years ago the answer to the question in the title of this review would have been, “unfortunately not much” or even “nothing”, likely eliciting knowing nods of agreement from oncologists. For the last 3 decades, SCLC has been notorious for its lack of progress, as drug after drug, over 60 of them, in fact, including inhibitors of VEGF, IGFR, mTOR, EGFR and HGF has failed and fallen by the wayside due to little or no impact on PFS or OS, while SCLC's cousin, NSCLC, has notched success after success with a spate of targeted treatment and immunotherapy regulatory approvals. However, a paradigm shift or, more appropriately, a ‘paradigm nudge’ is quietly underway in extensive stage SCLC with a series of agents that in early clinical trials have shown the potential to ‘lift the curse’ in SCLC, heretofore referred to as “a graveyard for drug development”. These agents, constituting the “best of what's new” in SCLC, and discussed in this review following a brief overview of the classification, epidemiology, prognosis and current treatment of SCLC, include checkpoint inhibitors, antibody-drug conjugates, PARP inhibitors, epigenetic inhibitor/innate immune activator, and an inhibitor of RNA polymerase II. Compared to NSCLC, the therapeutic options are still limited but with one or more successes to build momentum and drive long-overdue R&D and clinical investment the hope is that the approval floodgates may finally open.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ISSN:	1476-5586 1522-8002 1476-5586 1522-8002
DOI:	10.1016/j.neo.2017.07.007